
    
      This study was previously posted by Stromedix, Inc. In April, 2014, sponsorship of the trial
      was transferred to Biogen. The study drug name was changed from STX-100 to BG00011 and the
      study number was changed from STX-003 to 203PF201, to align with sponsor conventions.
    
  